Interferon lambda inhibits dengue virus replication in epithelial cells

Virology Journal

Volumn 12, Issue 1, 2015, Pages

  Palma Ocampo, Helen K ^a,b   Flores Alonso, Juan C ^a   Vallejo Ruiz, Verónica ^a   Reyes Leyva, Julio ^a   Flores Mendoza, Lilian ^a   Herrera Camacho, Irma ^b   Rosas Murrieta, Nora H ^b   Santos López, Gerardo ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

Dengue; DENV; DENV 2; IFN III; IFN ; IL 28A; IL 28B; IL 29; Interferon ; SOCS

Indexed keywords

BETA INTERFERON; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA 3; INTERLEUKIN 28; INTERLEUKIN 28 R1 SUBUNIT; INTERLEUKIN 28A; INTERLEUKIN 29; MESSENGER RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; 2',5' OLIGOADENYLATE SYNTHETASE; ANTIVIRUS AGENT; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; OAS1 PROTEIN, HUMAN;

ARTICLE; C33 A CELL LINE; CELL LINE; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERFERON STIMULATED GENE; MOLECULAR INTERACTION; MX1 GENE; NONHUMAN; OAS1 GENE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; SIGNAL TRANSDUCTION; VIRAL PHENOMENA AND FUNCTIONS; VIRAL TITER; VIRUS INHIBITION; VIRUS REPLICATION; BIOSYNTHESIS; BLOOD; DENGUE VIRUS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS LOAD;

2',5'-OLIGOADENYLATE SYNTHETASE; ANTIVIRAL AGENTS; DENGUE VIRUS; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKINS; MYXOVIRUS RESISTANCE PROTEINS; RNA, MESSENGER; VIRAL LOAD; VIRUS REPLICATION;

EID: 84942429080     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-015-0383-4     Document Type: Article

References (42)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-7. doi: 10.1038/nature12060.
2. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8(12 Suppl):S7-16. doi: 10.1038/nrmicro2460.
3. Perera R, Kuhn RJ. Structural proteomics of dengue virus. Curr Opin Microbiol. 2008;11(4):369-77. doi: 10.1016/j.mib.2008.06.004.
4. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva, Switzerland: WHO; 1997.
5. Hales S, de Wet N, Maindonald J, Woodward A. Potential effect of population and climate changes on global distribution of dengue fever: an empirical model. Lancet. 2002;360(9336):830-4. doi: 10.1016/S0140-6736(02)09964-6.
6. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Vvirol. 2008;89(Pt 1):1-47. doi: 10.1099/vir.0.83391-0.
7. Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, Ashour J, Ayllon J, Fernandez-Sesma A. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J Virol. 2010;84(19):9760-74. doi: 10.1128/JVI.01051-10.
8. de Weerd NA, Nguyen T. The interferons and their receptors - distribution and regulation. Immunol Cell Biol. 2012;90(5):483-91. doi: 10.1038/icb.2012.9.
9. Stetson DB, Medzhitov R. Antiviral defense: interferons and beyond. J Exp Med. 2006;203(8):1837-41. doi: 10.1084/jem.20061377.
10. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69-77. doi: 10.1038/ni875ni875.
11. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63-8. doi: 10.1038/ni873ni873.
12. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164-71. doi: 10.1038/ng.2521.
13. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009;86(1):23-32. doi: 10.1189/jlb.1208761.
14. Pagliaccetti NE, Robek MD. Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. J Interferon Cytokine Res. 2010;30(8):585-90. doi: 10.1089/jir.2010.0060.
15. Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol. 2009;83(8):3834-42. doi: 10.1128/JVI.01773-08.
16. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4(3), e1000017. doi: 10.1371/journal.ppat.1000017.
17. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009;10(8):702-14. doi: 10.1038/gene.2009.72.
18. Limonta Vidal M, Ramírez Albajes V, López Saura P, Aguilera A, Pentón E, Barcelona S, et al. Use of leukocyte interferon during an epidemic outbreak of haemorragic dengue (Type II) in Cuba. Interferon Biotecnol. 1984;1(3):15-22.
19. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25(3):283-91.
20. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52(3):822-32. doi: 10.1002/hep.23743.
21. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9(6):1003-11.
22. Stoltz M, Klingstrom J. Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection. J Virol. 2010;84(18):9140-8. doi: 10.1128/JVI.00717-10.
23. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol. 2008;180(4):2474-85.
24. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008;4(9), e1000151. doi: 10.1371/journal.ppat.1000151.
25. De La Cruz Hernandez SI, Puerta-Guardo H, Flores-Aguilar H, Gonzalez-Mateos S, Lopez-Martinez I, Ortiz-Navarrete V, et al. A strong interferon response correlates with a milder dengue clinical condition. J Clin Virol. 2014;60(3):196-9. doi: 10.1016/j.jcv.2014.04.002.
26. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006;80(9):4501-9. doi: 10.1128/JVI.80.9.4501-4509.2006.
27. Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology. 2010;401(2):197-206. doi: 10.1016/j.virol.2010.02.022.
28. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005;79(6):3851-4. doi: 10.1128/JVI.79.6.3851-3854.2005.
29. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 2006;44(4):896-906. doi: 10.1002/hep.21312.
30. Ma D, Jiang D, Qing M, Weidner JM, Qu X, Guo H, et al. Antiviral effect of interferon lambda against West Nile virus. Antiviral Res. 2009;83(1):53-60. doi: 10.1016/j.antiviral.2009.03.006.
31. Desmyter J, Melnick JL, Rawls WE. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol. 1968;2(10):955-61.
32. Diaz MO, Ziemin S, Le Beau MM, Pitha P, Smith SD, Chilcote RR, et al. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A. 1988;85(14):5259-63.
33. Lin RJ, Yu HP, Chang BL, Tang WC, Liao CL, Lin YL. Distinct antiviral roles for human 2′,5′-oligoadenylate synthetase family members against dengue virus infection. J Immunol. 2009;183(12):8035-43. doi: 10.4049/jimmunol.0902728.
34. Li XL, Blackford JA, Hassel BA. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol. 1998;72(4):2752-9.
35. Iversen MB, Paludan SR. Mechanisms of type III interferon expression. J Interferon Cytokine Res. 2010;30(8):573-8. doi: 10.1089/jir.2010.0063.
36. Osterlund P, Veckman V, Siren J, Klucher KM, Hiscott J, Matikainen S, et al. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol. 2005;79(15):9608-17. doi: 10.1128/JVI.79.15.9608-9617.2005.
37. Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. 2005;174(4):1932-7.
38. Melchjorsen J, Siren J, Julkunen I, Paludan SR, Matikainen S. Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J Gen Virol. 2006;87(Pt 5):1099-108. doi: 10.1099/vir.0.81541-0.
39. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology. 2013;144(2):414-25. doi: 10.1053/j.gastro.2012.10.034. e7.
40. Harinasuta C, Nimmanitya S, Titsyakorn U. The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand. Southeast Asian J Trop Med Public Health. 1985;16(2):332-6.
41. Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27(6):423-31. doi: 10.1007/s11096-005-1319-7.
42. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol. 2000;74(17):7814-23.